Effects of epoetin-α on quality of life of cancer patients with solid tumors receiving chemotherapy

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 693-702

  Christodoulou, C ^a   Dafni, U ^b   Aravantinos, G ^c   Koutras, A ^d   Samantas, E ^c   Karina, M ^e   Janinis, J ^f   Papakostas, P ^g   Skarlos, D ^a   Kalofonos, H P ^d   Fountzilas, G ^e  

^a METROPOLITAN HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f Social Security Org Oncology Center   (Greece)

^g Ippokration Hospital Thessaloniki   (Greece)

Author keywords

Chemotherapy; Epoetin ; Hemoglobin; Quality of life; Solid tumors

Indexed keywords

CARBOPLATIN; CISPLATIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA SUBSCALE SCORE; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; EMOTIONAL WELL BEING; FATIGUE SUBSCALE; FATIGUE TOTAL SCORE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA SCALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; FUNCTIONAL WELL BEING; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NON FATIGUE SUBSCALE; PHYSICAL WELL BEING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SOCIAL FAMILY WELL BEING; SOLID TUMOR; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61449092986     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H and Barnas U: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322: 1693-1699, 1990.
2. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, Gordon MS, Lichtin AE, Wade JL 3rd, Woolf S and Aronson N: Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93: 1204-1214, 2001.
3. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S and Vadhan-Raj, S, for the Procrit Study Group: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218-1234, 1997.
4. Demetri GD, Kris M, Wade J, Degos L and Cella D: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study, for the Procrit Study Group. J Clin Oncol 16: 3412-3425, 1998.
5. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E and Einhorn LH: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875-2882, 2001.
6. Desai J and Demetri GD: Recombinant human erythropoietin in cancer-related anemia: an evidence-based review. Best Pract Res Clin Haematol 18: 389-406, 2005.
7. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E and Rapoport B: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-2874, 2001
8. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R and Morton RF: Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23: 2606-2617, 2005.
9. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C and Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003.
10. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X and Vercammen E: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972, 2005.
11. Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, Janinis D, Pectasides D, Pavlidis N and Fountzilas G: Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 64: 102-110, 2003.
12. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34: 13-19, 1997.
13. Laird NM and Ware JH: Random-effects models for longitudinal data. Biometrics 38: 963-974, 1982.
14. Machin D, Campbell MJ, Payers PM and Pinol APY: Sample Size Tables for Clinical Studies, 2nd Edition. Oxford, Blackwell Science, 1997.
15. Cohen J: Statistical Power Analysis for the Behavioural Sciences, 2nd Edition. New Jersey, Lawrence Earlbaum, 1998.
16. Bottomley A, Thomas JR, van Steen K, Flechtner H and Djulbegovic B: Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol 3: 145-153, 2002.
17. Bohlius J, Langensiepen S, Schawarzer G, Seidenfeld J, Piper M, Bennet C and Engert A: Erythropoietin for patients with malignant disease, CD003407 ed, Cochrane Database Syst Rev 3, 2004.
18. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS and Levine MN: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25: 1027-1032, 2007.
19. Food and Drug Administartion Oncologic Drugs Advisory Committee Briefing Document. Continuing Reassessment of the Risks of Erythropoiesis-stimulating Agents (ESAS) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy: Washington, DC: US Food and Drug Administration http://www.fda.gov/ohrms/dockets/ac/07/briefmg/2007-4301b2-02-FDA.pdf, 2007.
20. Danish Head and Neck Cancer Group (DAHANCA): Study of the importance of novel erythropoiesis-stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck. Aarhus, Denmark: Aarhus University Hospital, 2007. http://www.dahanca.dk/ get_media_file.php?mediaid=125
21. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G and Littlewood TJ, Darbepoetin Alfa 20000161 Study Group: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 122: 394-403, 2003.
22. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M and Pajonk F: Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24: 4708-4713, 2006
23. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B and Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469-475, 2002.